Folyóiratcikkek tallózása szerző szerint "Módos, Orsolya"

1-9 / 9

A felső húgyúti urothel sejtes tumorok kezelése - hasonlóságok és különbségek a húgyhólyag urotheliális tumoraival

Kubik, András; Szarvas, Tibor; Módos, Orsolya; Keresztes Dávid; Horváth, András; Nyirády, Péter (2017)
Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data

Reis H; Krafft U; Niedworok C; Módos, Orsolya; Herold T; Behrendt M; Al-Ahmadie H; Hadaschik B; Nyirády, Péter; Szarvas, Tibor (2018)

Urachal cancer (UrC) is a rare but aggressive cancer. Due to overlapping histomorphology, discrimination of urachal from primary bladder adenocarcinomas (PBAC) and adenocarcinomas secondarily involving the bladder (particularly ...
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer

Szarvas, Tibor; Sevcenco, S; Módos, Orsolya; Keresztes, Dávid; Nyirády, Péter; Kubik, András; Romics, Miklós; Kovalszky, Ilona; Reis, H; Hadaschik, B; Shariat, SF; Kramer, G (2018)

OBJECTIVES: Docetaxel chemotherapy is a standard treatment for castration-resistant prostate cancer (CRPC). Rapidly expanding treatment options for CRPC provide reasonable alternatives for those who are resistant to ...
Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases

Szarvas, Tibor; Módos, Orsolya; Niedworok C; Reis H; Szendrői, Attila; Szász, Attila Marcell; Nyirády, Péter (2016)

BACKGROUND AND OBJECTIVES: Urachal carcinoma (UrC) is a rare and poorly investigated disease. Our current knowledge is mainly based on single-institutional studies. Despite growing interest in UrC, the included case numbers ...
MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer

Szarvas, Tibor; Sevcenco, S; Módos, Orsolya; Keresztes, Dávid; Nyirády, Péter; Csizmarik, Anita; Ristl, R; Puhr, M; Hoffmann, MJ; Niedworok, C; Hadaschik, B; Maj-Hes, A; Shariat, SF; Kramer, G (2018)

PURPOSE: To assess the predictive value of pre-chemotherapy MMP-7, sFas, FasL serum levels as well as their changes during therapy. PATIENTS AND METHODS: Serum levels of MMP-7, Fas and FasL were determined by ELISA in 96 ...
Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma - occurence and prognostic significance

Módos, Orsolya; Reis H; Niedworok C; Rubben H; Szendrői, Attila; Szász, Attila; Tímár, József; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollosi P; Nyirády, Péter; Szarvas, Tibor (2016)

PURPOSE: Targeted therapy represents an attractive alternative for rare tumors such as urachal carcinoma (UrC). The aim of this study was to assess the mutations of the most commonly affected 5 genes in the targetable ...
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas

Reis, H; van der Vos, KE; Niedworok, C; Herold, T; Módos, Orsolya; Szendrői, Attila; Hager, T; Ingenwerth, M; Vis, DJ; Behrendt, MA; de Jong, J; van der Heijden, MS; Peyronnet, B; Mathieu, R; Wiesweg, M; Ablat, J; Okon, K; Tolkach, Y; Keresztes, D; Nagy, N; Bremmer, F; Gaisa, NT; Chlosta, P; Kriegsmann, J; Kovalszky, Ilona; Timár, József; Kristiansen, G; Radzun, HJ; Knuchel, R; Schuler, M; Black, P; Rubben, H; Hadaschik, B; Schmid, KW; van Rhijn, BWG; Nyirády, Péter; Szarvas, Tibor (2018)

Urachal cancer (UrC) is a rare but aggressive malignancy often diagnosed in advanced stages requiring systemic treatment. Although cytotoxic chemotherapy is of limited effectiveness, prospective clinical studies can hardly ...
Urachal carcinoma of the bladder - impact of clinical and immunohistochemical parameters on prognosis

Niedworok C; Panitz M; Szarvas, Tibor; Reis H; Reis AC; Szendrői, Attila; Nyirády, Péter; Szász, Attila Marcell; Módos, Orsolya; Ruebben H; Vom Dorp F (2016)

PURPOSE: Urachal carcinoma of the bladder (UrC) is a rare malignancy. Its histological phenotype is similar to that of primary bladder adenocarcinomas and colorectal adenocarcinomas. The aim of this study was to explore ...
Why are upper tract urothelial carcinoma two different diseases?

Szarvas, Tibor; Módos, Orsolya; Horváth, András; Nyirády, Péter (2016)

1-9 / 9

Keresés

Összetett keresés

Tallózás

Teljes repozitórumban
Ebben a gyűjteményben

Hozzáférésem

Bejelentkezés

Folyóiratcikkek tallózása szerző szerint "Módos, Orsolya"

DSpace/Manakin Repository

Folyóiratcikkek tallózása szerző szerint "Módos, Orsolya"

Keresés

Tallózás

Teljes repozitórumban

Ebben a gyűjteményben

Hozzáférésem